Nephrogenic diabetes insipidus: Essential insights into the molecular background and potential therapies for treatment

Endocrine Reviews

Volumn 34, Issue 2, 2013, Pages 278-301

  Moeller, Hanne B ^a   Rittig, Søren ^b   Fenton, Robert A ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(2 CHLORO 4 PYRROLIDIN 1 YLBENZOYL) 2,3,4,5 TETRAHYDRO 1 BENZAZEPIN 5 YL] N PROPAN 2 YLACETAMIDE; [2 CHLORO 4 (3 METHYLPYRAZOL 1 YL)PHENYL] (6,11 DIHYDROPYRROLO[2,1 C][1,4]BENZODIAZEPIN 5 YL)METHANONE; AMILORIDE; AQUAPORIN 2; ARGIPRESSIN; BUTAPROST; CAY 10580; CONIVAPTAN; COPEPTIN; DESMOPRESSIN; FLUINDOSTATIN; HORMONE RECEPTOR STIMULATING AGENT; HYDROCHLOROTHIAZIDE; INDOMETACIN; LITHIUM; LIXIVAPTAN; MEVINOLIN; MFC 14; MFC 18; MOZAVAPTAN; ONO AE 329; OPC 51803; PHOSPHODIESTERASE INHIBITOR; RELCOVAPTAN; RETASPIMYCIN; ROLIPRAM; SATAVAPTAN; SILDENAFIL; SIMVASTATIN; TOLVAPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ACUTE KIDNEY FAILURE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; BODY WATER; CELL MEMBRANE; CHRONIC KIDNEY FAILURE; CYTOLOGY; DEHYDRATION; DIABETES INSIPIDUS; ELECTROLYTE DISTURBANCE; FAMILIAL NEUROHYPOPHYSEAL DIABETES INSIPIDUS; FLUID INTAKE; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; GENETICS; HUMAN; KIDNEY COLLECTING TUBULE; NEPHROGENIC DIABETES INSIPIDUS; NEUROHYPOPHYSEAL DIABETES INSIPIDUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSMOLALITY; PATHOPHYSIOLOGY; PHENOTYPE; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; URINE VOLUME;

ANIMALS; AQUAPORIN 2; ARGININE VASOPRESSIN; DIABETES INSIPIDUS, NEPHROGENIC; DISEASE MODELS, ANIMAL; HUMANS; MUTATION; RATS; RECEPTORS, VASOPRESSIN;

EID: 84876063984     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2012-1044     Document Type: Review

References (200)

1. Robertson GL. 1987 Physiology ofADHsecretion. Kidney Int. Suppl 21:S20-S26.
2. BourqueCW. 2008 Central mechanisms of osmosensation and systemic osmoregulation. Nat Rev Neurosci. 9:519-531.
3. Nielsen S, Frøkiaer J, Marples D, Kwon TH, Agre P, KnepperMA. 2002 Aquaporins in the kidney: from molecules to medicine. Physiol Rev. 82:205-244.
4. Robben JH, Knoers NV, Deen PM. 2006 Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol. 291:F257-F270.
5. Babey M, Kopp P, Robertson GL. 2011 Familial forms of diabetes insipidus: clinical and molecular characteristics. Nat Rev Endocrinol. 7:701-714.
6. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG. 1999 Association of _-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J Biol Chem. 274: 32248-32257.
7. Robertson GL. 1995 Diabetes insipidus. Endocrinol Metab Clin North Am. 24:549-572.
8. Ananthakrishnan S. 2009 Diabetes insipidus in pregnancy: etiology, evaluation, and management. Endocr Pract. 15: 377-382.
9. Heinke F, Labudde D. 2012 Membrane protein stability analyses by means of protein energy profiles in case of nephrogenic diabetes insipidus. Comput Math Methods Med. 2012:790281.
10. Robertson GL. 1988 Differential diagnosis of polyuria. Annu Rev Med. 39:425-442.
11. Fujiwara, TM,Bichet, DG .2005Molecularbiologyofhereditary diabetes insipidus. J Am Soc Nephrol. 16:2836-2846.
12. Singer I, Oster JR, Fishman LM. 1997 The management of diabetes insipidus in adults. Arch Intern Med. 157:1293-1301.
13. Makaryus AN, McFarlane SI. 2006 Diabetes insipidus: diagnosis and treatment of a complex disease. Cleve Clin J Med. 73:65-71.
14. Zerbe RL, Robertson GL. 1981 A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. N Engl J Med. 305: 1539-1546.
15. Kurokawa H, Fujisawa I, Nakano Y, Kimura H, Akagi K, Ikeda K, Uokawa K, Tanaka Y. 1998 Posterior lobe of the pituitary gland: correlation between signal intensity on T1-weighted MR images and vasopressin concentration. Radiology. 207:79-83.
16. Ranadive SA, Ersoy B, Favre H, Cheung CC, Rosenthal SM, Miller WL, Vaisse C. 2009 Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clin Endocrinol (Oxf). 71:388-393.
17. Morgenthaler NG, Struck J, Alonso C, Bergmann A. 2006 Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 52:112-119.
18. Christensen JH, Rittig S. 2006 Familial neurohypophyseal diabetes insipidus-an update. Semin Nephrol. 26:209-223.
19. Burbach JP, Luckman SM, Murphy D, Gainer H. 2001 Gene regulation in the magnocellular hypothalamoneurohypophysial system. Physiol Rev. 81:1197-1267.
20. Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, Cooper DN. 2009 The human gene mutation database: 2008 update. Genome Med. 1:13.
21. Arima H, Oiso Y. 2010 Mechanisms underlying progressive polyuria in familial neurohypophysial diabetes insipidus. J Neuroendocrinol. 22:754-757.
22. Willcutts MD, Felner E, White PC. 1999 Autosomal recessive familial neurohypophyseal diabetes insipidus with continued secretion of mutant weakly active vasopressin. Hum Mol Genet. 8:1303-1307.
23. AbuLibdeh A, Levy-Khademi F, Abdulhadi-Atwan M, Bosin E, Korner M, White PC, Zangen DH. 2010 Autosomal recessive familial neurohypophyseal diabetes insipidus: onset in early infancy. Eur J Endocrinol. 162:221-226.
24. Habiby R, Robertson GL, Kaplowitz PB, Rittig S. 1996 A Novel X-linked form of familial neurophpophyseal diabetes insipidus. J Invest Med. 44:341A (Abstract).
25. Si-Hoe SL, De Bree FM, Nijenhuis M, Davies JE, Howell LM, Tinley H, Waller SJ, Zeng Q, Zalm R, Sonnemans M, Van Leeuwen FW, Burbach JP, Murphy D. 2000 Endoplasmic reticulum derangement in hypothalamic neurons of rats expressing a familial neurohypophyseal diabetes insipidus mutant vasopressin transgene. FASEB J. 14: 1680-1684.
26. Birk J, FribergMA,Prescianotto-Baschong C, SpiessM,Rutishauser J. 2009 Dominant pro-vasopressin mutants that cause diabetes insipidus form disulfide-linked fibrillar aggregates in the endoplasmic reticulum. J Cell Sci. 122(Pt 21): 3994-4002.
27. Ito M, Jameson JL, Ito M. 1997 Molecular basis of autosomal dominant neurohypophyseal diabetes insipidus. Cellular toxicity caused by the accumulation of mutant vasopressin precursors within the endoplasmic reticulum. J Clin Invest. 99:1897-1905.
28. Ito M, Yu RN, Jameson JL. 1999 Mutant vasopressin precursors that cause autosomal dominant neurohypophyseal diabetes insipidus retain dimerization and impair the secretion of wild-type proteins. J Biol Chem. 274:9029-9037.
29. Russell TA, Ito M, Ito M, Yu RN, Martinson FA, Weiss J,Jameson JL. 2003 A murine model of autosomal dominant neurohypophyseal diabetes insipidus reveals progressive loss of vasopressin-producing neurons. J Clin Invest. 112: 1697-1706.
30. Hayashi M, Arima H, Ozaki N, Morishita Y, Hiroi M, Ozaki N, Nagasaki H, Kinoshita N, Ueda M, Shiota A, Oiso Y. 2009 Progressive polyuria without vasopressin neuron loss in a mouse model for familial neurohypophysial diabetes insipidus. Am J Physiol Regul Integr Comp Physiol. 296:R1641-R1649.
31. Valtin H, Schroeder HA. 1964 Familial hypothalamic diabetes insipidus in rats (Brattleboro strain). Am J Physiol. 206:425-430.
32. Schmale H, Richter D. 1984 Single base deletion in the vasopressin gene is the cause of diabetes insipidus in Brattleboro rats. Nature. 308:705-709.
33. Kim JK, Summer SN, Wood WM, Brown JL, Schrier RW. 1997 Arginine vasopressin secretion with mutants of wildtype and Brattleboro rats AVP gene. J Am Soc Nephrol. 8:1863-1869.
34. DiGiovanni SR, Nielsen S, Christensen EI, Knepper MA. 1994 Regulation of collecting duct water channel expression by vasopressin in Brattleboro rat. Proc Natl Acad Sci USA. 91:8984-8988.
35. Terris J, Ecelbarger CA, Nielsen S, Knepper MA. 1996 Long-term regulation of four renal aquaporins in rats.AmJ Physiol. 271(Pt 2):F414-F422.
36. Fenton RA. 2009 Essential role of vasopressin-regulated urea transport processes in the mammalian kidney. Pflugers Arch. 458:169-177.
37. Fenton RA, Knepper MA. 2007 Mouse models and the urinary concentrating mechanism in the new millennium. Physiol Rev. 87:1083-1112.
38. Bockenhauer D, van't Hoff W, Dattani M, Lehnhardt A, Subtirelu M, Hildebrandt F, Bichet DG. 2010 Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases. Nephron Physiol. 116:p23-p29.
39. Wesche D, Deen PM, Knoers NV. 2012 Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr Nephrol. 2012 27:2183-2204.
40. van Lieburg AF, Knoers NV, Monnens LA. 1999 Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol. 10: 1958-1964.
41. Bichet DG. 2006 Nephrogenic diabetes insipidus. Adv Chronic Kidney Dis. 13:96-104.
42. Bichet DG. 2006 Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 26:224-233.
43. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W. 1992 Molecular cloning of the receptor for human antidiuretic hormone. Nature. 357:333-335.
44. Barberis C, Mouillac B, Durroux T. 1998 Structural bases of vasopressin/oxytocin receptor function. J Endocrinol. 156:223-229.
45. Slusarz MJ, Giełdoń A, Slusarz R, Ciarkowski J. 2006 Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptorsmolecular dynamics study of the activated receptor-vasopressin-G(_) systems. J Pept Sci. 12:180-189.
46. Slusarz MJ, Sikorska E, Slusarz R, Ciarkowski J. 2006 Molecular docking-based study of vasopressin analogues modified at positions 2 and 3 with N-methylphenylalanine: influence on receptor-bound conformations and interactions with vasopressin and oxytocin receptors. J Med Chem. 49:2463-2469.
47. Rosenthal W, Seibold A, Antaramian A, Lonergan M, Arthus MF, Hendy GN, Birnbaumer M, Bichet DG. 1992 Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature. 359:233-235.
48. Knoers NV, Deen PM. 2001 Molecular and cellular defects in nephrogenic diabetes insipidus. Pediatr Nephrol. 16: 1146-1152.
49. Arthus MF, Lonergan M, Crumley MJ, Naumova AK, Morin D, De Marco LA, Kaplan BS, Robertson GL, Sasaki S, Morgan K, Bichet DG, Fujiwara TM. 2000 Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol. 11:1044-1054.
50. SatohM,Ogikubo S, Yoshizawa-Ogasawara A. 2008 Correlation between clinical phenotypes and X-inactivation patterns in six female carriers with heterozygote vasopressin type 2 receptor gene mutations. Endocr J. 55:277-284.
51. FaerchM,Corydon TJ, Rittig S, Christensen JH, Hertz JM, Jendle J. 2010 Skewed X-chromosome inactivation causing diagnostic misinterpretation in congenital nephrogenic diabetes insipidus. Scand J Urol Nephrol. 44:324-330.
52. Bichet DG. 2008 Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin Nephrol. 28:245-251.
53. Spanakis E, Milord E, Gragnoli C. 2008 AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance. J Cell Physiol. 217: 605-617.
54. Tegay DH, Lane AH, Roohi J, Hatchwell E. 2007 Contiguous gene deletion involving L1CAM and AVPR2 causes X-linked hydrocephalus with nephrogenic diabetes insipidus. Am J Med Genet A. 143:594-598.
55. Knops NB, Bos KK, Kerstjens M, van Dael K, Vos YJ. 2008 Nephrogenic diabetes insipidus in a patient with L1 syndrome: a new report of a contiguous gene deletion syndrome includingL1CAMand AVPR2.AmJ Med Genet A. 146A:1853-1858.
56. Morin D, Tenenbaum J, Ranchin B, Durroux T. 2012 Nephrogenic syndrome of inappropriate antidiuresis. Int J Pediatr. 2012:937175.
57. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE. 2005 Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 352:1884-1890.
58. Ranchin B, Boury-Jamot M, Blanchard G, Dubourg L, Hadj-Aïssa A, Morin D, Durroux T, Cochat P, Bricca G, Verbavatz JM, Geelen G. 2010 Familial nephrogenic syndrome of inappropriate antidiuresis: dissociation between aquaporin-2 and vasopressin excretion. J Clin Endocrinol Metab. 95:E37-E43.
59. Decaux G, Vandergheynst F, Bouko Y, Parma J, Vassart G, Vilain C. 2007 Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in menand women from a large pedigree. J Am Soc Nephrol. 18: 606-612.
60. Bes DF, Mendilaharzu H, FenwickRG,Arrizurieta E. 2007 Hyponatremia resulting from arginine vasopressin receptor 2 gene mutation. Pediatr Nephrol. 22:463-466.
61. Gupta S, Cheetham TD, Lambert HJ, Roberts C, Bourn D, Coulthard MG, Ball SG. 2009 Thirst perception and arginine vasopressin production in a kindred with an activating mutation of the type 2 vasopressin receptor: the pathophysiology of nephrogenic syndrome of inappropriate antidiuresis. Eur J Endocrinol. 161:503-508.
62. Cho YH, Gitelman S, Rosenthal S, Ambler G. 2009 Longterm outcomes in a family with nephrogenic syndrome of inappropriate antidiuresis. Int J Pediatr Endocrinol. 2009: 431527.
63. Marcialis MA, Faa' V, Fanos V, Puddu M, Pintus MC, Cao A, Rosatelli MC. 2008 Neonatal onset of nephrogenic syndrome of inappropriate antidiuresis. Pediatr Nephrol. 23: 2267-2271.
64. Tenenbaum J, AyoubMA,Perkovska S, Adra-Delenne AL, Mendre C, Ranchin B, Bricca G, Geelen G, Mouillac B, Durroux T, Morin D. 2009 The constitutively active V2 receptor mutants conferringNSIADare weakly sensitive to agonist and antagonist regulation. PLoS One. 4:e8383.
65. Nossent AY, Robben JH, Deen PM, Vos HL, Rosendaal FR, Doggen CJ, Hansen JL, Sheikh SP, Bertina RM, Eikenboom JC. 2010 Functional variation in the arginine vasopressin 2 receptor as a modifier of human plasma von Willebrand factor levels. J Thromb Haemost. 8:1547-1554.
66. Yun J, Schö neberg T, Liu J, Schulz A, Ecelbarger CA, Promeneur D, Nielsen S, Sheng H, Grinberg A, Deng C, Wess J. 2000 Generation and phenotype of mice harboring a nonsense mutation in the V2 vasopressin receptor gene. J Clin Invest. 106:1361-1371.
67. Schliebe N, Strotmann R, Busse K, Mitschke D, Biebermann H, Schomburg L, Kö hrle J, Bä r J, Rö mpler H, Wess J, Schö neberg T, Sangkuhl K. 2008 V2 vasopressin receptor deficiency causes changes in expression and function of renal and hypothalamic components involved in electrolyte and water homeostasis. Am J Physiol Renal Physiol. 295:F1177-F1190.
68. Li JH, Chou CL, Li B, Gavrilova O, Eisner C, Schnermann J, Anderson SA, Deng CX, Knepper MA, Wess J. 2009 A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J Clin Invest. 119:3115-3126.
69. Ala Y, Morin D, Mouillac B, Sabatier N, Vargas R, Cotte N, Déchaux M, Antignac C, Arthus MF, Lonergan M, Turner MS, BalestreMN,Alonso G, HibertM,Barberis C, Hendy GN, Bichet DG, Jard S. 1998 Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype. J Am Soc Nephrol. 9:1861-1872.
70. Bockenhauer D, Carpentier E, Rochdi D, Van't Hoff W, Breton B, Bernier V, Bouvier M, Bichet DG. 2009 Vasopressin type 2 receptorV88Mmutation: molecular basis of partial and complete nephrogenic diabetes insipidus. Nephron Physiol. 114:p1-p10.
71. Rochdi MD, Vargas GA, Carpentier E, Oligny-Longpré G, Chen S, Kovoor A, Gitelman SE, Rosenthal SM, von Zastrow M, Bouvier M. 2010 Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Mol Pharmacol. 77:836-845.
72. Mizuno H, Sugiyama Y, Ohro Y, Imamine H, Kobayashi M, Sasaki S, Uchida S, Togari H. 2004 Clinical characteristics of eight patients with congenital nephrogenic diabetes insipidus. Endocrine. 24:55-59.
73. Faerch M, Christensen JH, Corydon TJ, Kamperis K, de Zegher F, Gregersen N, Robertson GL, Rittig S. 2008 Partial nephrogenic diabetes insipidus caused by a novel mutation in the AVPR2 gene. Clin Endocrinol (Oxf). 68:395-403.
74. Robertson G, Nayak S, Kopp P, Johansson JO, Rittig S. 2001 The cause of vasopressin responsive familial diabetes insipidus in a large Swedish kindred with X-linked recessive mode of transmission. J Invest Med. 49:58A (Abstract).
75. Robertson GL, Scheidler JA. 1981 A newly recognized variant of familial nephrogenic diabetes insipidus distinguished by partial resistance to vasopressin (type II). Clin Res. 29:555A (Abstract).
76. Robertson GL, Kopp P, Bichet DG. Variations in clinical phenotype associated with different mutations of the V2 receptor gene in X-linked recessive congenital nephrogenic DI (xCNDI). Program of the Nephrogenic Diabetes Insipidus Foundation Global Conference, La Jolla, CA, 2000, p 11 (Abstract).
77. Neocleous V, Skordis N, Shammas C, Efstathiou E, Mastroyiannopoulos NP, Phylactou LA. 2012 Identification and characterization of a novel X-linked AVPR2 mutation causing partial nephrogenic diabetes insipidus: a case report and review of the literature. Metabolism. 61:922-930.
78. Canfield MC, Tamarappoo BK, Moses AM, Verkman AS, Holtzman EJ. 1997 Identification and characterization of aquaporin-2 water channel mutations causing nephrogenic diabetes insipidus with partial vasopressin response. Hum Mol Genet. 6:1865-1871.
79. Mulders SM, Knoers NV, Van Lieburg AF, Monnens LA, Leumann E,Wühl E, Schober E, Rijss JP, Van Os CH, Deen PM. 1997 Newmutations in theAQP2gene in nephrogenic diabetes insipidus resulting in functional but misrouted water channels. J Am Soc Nephrol. 8:242-248.
80. de Mattia F, Savelkoul PJ, Kamsteeg EJ, Konings IB, van der Sluijs P, Mallmann R, Oksche A, Deen PM. 2005 Lack of arginine vasopressin-induced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus. J Am Soc Nephrol. 16:2872-2880.
81. Savelkoul PJ, De Mattia F, Li Y, Kamsteeg EJ, Konings IB, van der Sluijs P, Deen PM. 2009 p.R254Q mutation in the aquaporin-2 water channel causing dominant nephrogenic diabetes insipidus is due to a lack of arginine vasopressininduced phosphorylation. Hum Mutat. 30:E891-E903.
82. Marr N, Bichet DG, Hoefs S, Savelkoul PJ, Konings IB, De Mattia F, Graat MP, Arthus MF, Lonergan M, Fujiwara TM, Knoers NV, Landau D, Balfe WJ, Oksche A, Rosenthal W,Müller D, Van Os CH, Deen PM. 2002 Cellbiologic and functional analyses of five new Aquaporin-2 missense mutations that cause recessive nephrogenic diabetes insipidus. J Am Soc Nephrol. 13:2267-2277.83.
83. Kuwahara M, Iwai K, Ooeda T, Igarashi T, Ogawa E, Katsushima Y, Shinbo I, Uchida S, Terada Y, Arthus MF, Lonergan M, Fujiwara TM, Bichet DG, Marumo F, Sasaki S. 2001 Three families with autosomal dominant nephrogenic diabetes insipidus caused by aquaporin-2 mutations in the C-terminus. Am J Hum Genet. 69:738-748.
84. Mulders SM, Bichet DG, Rijss JP, Kamsteeg EJ, Arthus MF,LonerganM,FujiwaraM,Morgan K, Leijendekker R, van der Sluijs P, van Os CH, Deen PM. 1998 An aquaporin-2 water channel mutant which causes autosomal dominant nephrogenic diabetes insipidus is retained in the Golgi complex. J Clin Invest. 102:57-66.
85. Sasaki S, Fushimi K, Saito H, Saito F, Uchida S, Ishibashi K, Kuwahara M, Ikeuchi T, Inui K, Nakajima K. 1994 Cloning, characterization, and chromosomal mapping of human aquaporin of collecting duct. J Clin Invest. 93: 1250-1256.
86. Schenk AD, Werten PJ, Scheuring S, de Groot BL, Mü ller SA, Stahlberg H, Philippsen A, Engel A. 2005 The 4.5 A structure of human AQP2. J Mol Biol. 350:278-289.
87. Moeller HB, Olesen ET, Fenton RA. 2011 Regulation of the water channel aquaporin-2 by posttranslational modification. Am J Physiol Renal Physiol. 300:F1062-F1073.
88. Hoffert JD, Pisitkun T, Wang G, Shen RF, Knepper MA. 2006 Quantitative phosphoproteomics of vasopressinsensitive renal cells: regulation of aquaporin-2 phosphorylation at two sites. Proc Natl Acad Sci USA. 103:7159-7164.
89. Fushimi K, Sasaki S, Marumo F. 1997 Phosphorylation of serine 256 is required for cAMP-dependent regulatory exocytosis of the aquaporin-2 water channel. J Biol Chem. 272:14800-14804.
90. Kamsteeg EJ, Heijnen I, van Os CH, Deen PM. 2000 The subcellular localization of an aquaporin-2 tetramer depends on the stoichiometry of phosphorylated and nonphosphorylated monomers. J Cell Biol. 151:919-930.
91. Katsura T, Gustafson CE, Ausiello DA, Brown D. 1997 Protein kinase A phosphorylation is involved in regulated exocytosis of aquaporin-2 in transfected LLC-PK1 cells. Am J Physiol. 272(Pt 2):F817-F822.
92. Moeller HB, Knepper MA, Fenton RA. 2009 Serine 269 phosphorylated aquaporin-2 is targeted to the apical membrane of collecting duct principal cells. Kidney Int. 75:295-303.
93. Moeller HB, Praetorius J, Rützler MR, Fenton RA. 2010 Phosphorylation of aquaporin-2 regulates its endocytosis and protein-protein interactions. Proc Natl Acad Sci USA. 107:424-429.
94. Hoffert JD, Fenton RA, Moeller HB, Simons B, Tchapyjnikov D, McDill BW, Yu MJ, Pisitkun T, Chen F, Knepper MA. 2008 Vasopressin-stimulated increase in phosphorylation at Ser269 potentiates plasma membrane retention of aquaporin-2. J Biol Chem. 283:24617-24627.
95. van Lieburg AF, Verdijk MA, Knoers VV, van Essen AJ, Proesmans W, Mallmann R, Monnens LA, van Oost BA, van Os CH, Deen PM. 1994 Patients with autosomal nephrogenic diabetes insipidus homozygous for mutations in the aquaporin 2 water-channel gene. Am J Hum Genet. 55:648-652.
96. Rojek A, Füchtbauer EM, Kwon TH, Frøkiaer J, Nielsen S. 2006 Severe urinary concentrating defect in renal collecting duct-selective AQP2 conditional-knockout mice. Proc Natl Acad Sci USA. 103:6037-6042.
97. Yang B, Zhao D, Qian L, Verkman AS. 2006 Mouse model of inducible nephrogenic diabetes insipidus produced by floxed aquaporin-2 gene deleltion. Am J Physiol Renal Physiol. 291:F465-F472.
98. MaT, Song Y, Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS. 2000 Nephrogenic diabetes insipidus in mice lacking aquaporin-3 water channels. Proc Natl Acad Sci USA. 97:4386-4391.
99. Ma T, Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS. 1998 Severely impaired urinary concentrating ability in transgenic mice lacking aquaporin-1 water channels. J Biol Chem. 273:4296-4299.
100. Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS. 2001 Neonatal mortality in an aquaporin-2 knock-in mouse model of recessive nephrogenic diabetes insipidus. J Biol Chem. 276:2775-2779.
101. Yang B, Zhao D, Verkman AS. 2009 Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation. FASEB J. 23:503-512.
102. Lloyd DJ, Hall FW, Tarantino LM, Gekakis N. 2005 Diabetes insipidus in mice with a mutation in aquaporin-2. PLoS Genet. 1:e20.
103. Deen PM, Croes H, van Aubel RA, Ginsel LA, van Os CH. 1995 Water channels encoded by mutant aquaporin-2 genes in nephrogenic diabetes insipidus are impaired in their cellular routing. J Clin Invest. 95:2291-2296.
104. Deen PM, Verdijk MA, Knoers NV, Wieringa B, Monnens LA, van Os CH, van Oost BA. 1994 Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science. 264:92-95.
105. Lin SH, Bichet DG, Sasaki S, Kuwahara M, Arthus MF, Lonergan M, Lin YF. 2002 Two novel aquaporin-2 mutations responsible for congenital nephrogenic diabetes insipidus in Chinese families. J Clin Endocrinol Metab. 87: 2694-2700.
106. Marr N, Kamsteeg EJ, van Raak M, van Os CH, Deen PM. 2001 Functionality of aquaporin-2 missense mutants in recessive nephrogenic diabetes insipidus. Pflugers Arch. 442:73-77.
107. Leduc-Nadeau A, Lussier Y, Arthus MF, Lonergan M, Martinez-Aguayo A, Riveira-Munoz E, Devuyst O, Bissonnette P, Bichet DG. 2010Newautosomal recessive mutations in aquaporin-2 causing nephrogenic diabetes insipidus through deficient targeting display normal expression in Xenopus oocytes. J Physiol. 588(Pt 12): 2205-2218.
108. Kamsteeg EJ, Bichet DG, Konings IB, Nivet H, Lonergan M, Arthus MF, van Os CH, Deen PM. 2003 Reversed polarized delivery of an aquaporin-2 mutant causes dominant nephrogenic diabetes insipidus. J Cell Biol. 163: 1099-1109.
109. Boone M, Deen PM. 2009 Congenital nephrogenic diabetes insipidus: what can we learn from mouse models? Exp Physiol. 94:186-190.
110. Kamsteeg EJ, StoffelsM,TammaG, Konings IB, DeenPM. 2009 Repulsion between Lys258 and upstream arginines explains the missorting of the AQP2 mutant p.Glu258Lysin nephrogenic diabetes insipidus. Hum Mutat. 30:1387-1396.
111. Sohara E, Rai T, Yang SS, Uchida K, Nitta K, Horita S, OhnoM,Harada A, Sasaki S, Uchida S. 2006 Pathogenesis and treatment of autosomal-dominant nephrogenic diabetes insipidus caused by an aquaporin 2 mutation. Proc Natl Acad Sci USA. 103:14217-14222.
112. Kwon TH, Nielsen J, Møller HB, Fenton RA, Nielsen S, Frøkiaer J. 2009 Aquaporins in the kidney. Handb Exp Pharmacol. 190:95-132.
113. Garofeanu CG, Weir M, Rosas-Arellano MP, Henson G, Garg AX, Clark WF. 2005 Causes of reversible nephrogenic diabetes insipidus: a systematic review. Am J Kidney Dis. 45:626-637.
114. Grü nfeld JP, Rossier BC. 2009 Lithium nephrotoxicity revisited. Nat Rev Nephrol. 5:270-276.
115. Bedford JJ, Leader JP, Jing R, Walker LJ, Klein JD, Sands JM, Walker RJ. 2008 Amiloride restores renal medullary osmolytes in lithium-induced nephrogenic diabetes insipidus. Am J Physiol Renal Physiol. 294:F812-F820.
116. Crawford JD, Kennedy GC. 1959 Animal physiology: chlorothiazide in diabetes insipidus. Nature. 183:891-892.
117. Kortenoeven ML, Li Y, Shaw S, Gaeggeler HP, Rossier BC, Wetzels JF, Deen PM. 2009 Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int. 76:44-53.
118. Christensen BM, Zuber AM, Loffing J, Stehle JC, Deen PM, Rossier BC, Hummler E. 2011_ENaC-mediated lithium absorption promotes nephrogenic diabetes insipidus. J Am Soc Nephrol. 22:253-261.
119. Christensen S, Kusano E, Yusufi AN, Murayama N, Dousa TP. 1985 Pathogenesis of nephrogenic diabetes insipidus due to chronic administration of lithium in rats. J Clin Invest. 75:1869-1879.
120. Kwon TH, Laursen UH, Marples D, Maunsbach AB, Knepper MA, Frokiaer J, Nielsen S. 2000 Altered expression of renal AQPs and Na(_) transporters in rats with lithium-induced NDI. Am J Physiol Renal Physiol. 279: F552-F564.
121. Marples D, Christensen S, Christensen EI, Ottosen PD, Nielsen S. 1995 Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest. 95:1838-1845.
122. Li Y, Shaw S, Kamsteeg EJ, Vandewalle A, Deen PM. 2006 Development of lithium-induced nephrogenic diabetes insipidus is dissociated from adenylyl cyclase activity. J Am Soc Nephrol. 17:1063-1072.
123. Boton R, Gaviria M, Batlle DC. 1987 Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis. 10:329-345.
124. Nielsen J, Hoffert JD, Knepper MA, Agre P, Nielsen S, Fenton RA. 2008 Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation. Proc Natl Acad Sci USA. 105:3634-3639.
125. Cogan E, Svoboda M, Abramow M. 1987 Mechanisms of lithium-vasopressin interaction in rabbit cortical collecting tubule. Am J Physiol. 252(Pt 2):F1080-F1087.
126. Cogan E, Abramow M. 1986 Inhibition by lithium of the hydroosmotic action of vasopressin in the isolated perfused cortical collecting tubule of the rabbit. J Clin Invest. 77:1507-1514.
127. Christensen BM, Kim YH, Kwon TH, Nielsen S. 2006 Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Physiol. 291:F39-F48.
128. Christensen BM, Marples D, Kim YH, Wang W, Frøkiaer J, Nielsen S. 2004 Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI. Am J Physiol Cell Physiol. 286:C952-C964.
129. Castell DO, Sparks HA. 1965 Nephrogenic diabetes insipidus due to demethylchlortetracycline hydrochloride. JAMA. 193:237-239.
130. Torin DE. 1967 Nephrogenic diabetes insipidus induced by demethylchlortetracycline (Declomycin). Calif Med. 107:420-422.
131. Roth H, Becker KL, Shalhoub RJ, Katz S. 1967 Nephrotoxicity of demethylchlortetracycline hydrochloride. A prospective study. Arch Intern Med. 120:433-435.
132. Singer I, Rotenberg D. 1973 Demeclocycline-induced nephrogenic diabetes insipidus. In-vivo and in-vitro studies. Ann Intern Med. 79:679-683.
133. Cherrill DA, Stote RM, Birge JR, Singer I. 1975 Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med. 83:654-656.
134. Navarro JF, Quereda C, Quereda C, Gallego N, Antela A, Mora C, Ortuno J. 1996 Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis. 27:431-434.
135. Metzger NL, Varney Gill KL. 2009 Nephrogenic diabetes insipidus induced by two amphotericin B liposomal formulations. Pharmacotherapy. 29:613-620.
136. Skinner R. 2003 Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol. 41:190-197.
137. Marples D, Frøkiaer J, Dørup J, Knepper MA, Nielsen S. 1996 Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest. 97:1960-1968.
138. Wang W, Li C, Kwon TH, Knepper MA, Frøkiaer J, Nielsen S. 2002 AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors. Am J Physiol Renal Physiol. 283: F1313-F1325.
139. Sands JM, Flores FX, Kato A, Baum MA, Brown EM, Ward DT, Hebert SC, Harris HW. 1998 Vasopressin-elicited water and urea permeabilities are altered in IMCD in hypercalcemic rats. Am J Physiol. 274(Pt 2):F978-F985.
140. Morris RG, Hoorn EJ, Knepper MA. 2006 Hypokalemia in a mouse model of Gitelman's syndrome. Am J Physiol Renal Physiol. 290:F1416-F1420.
141. Patra S, Nadri G, Chowdhary H, Pemde HK, Singh V, Chandra J. 2011 Nephrogenic diabetes insipidus with idiopathic Fanconi's syndrome in a child who presented as vitamin D resistant rickets. Indian J Endocrinol Metab. 15:331-333.
142. Wang W, Li C, Kwon TH, Miller RT, KnepperMA,Frøkiaer J, Nielsen S. 2004 Reduced expression of renal Na_ transporters in rats with PTH-induced hypercalcemia. Am J Physiol Renal Physiol. 286:F534-F545.143.
143. Elkjaer ML, Kwon TH, Wang W, Nielsen J, Knepper MA, Frøkiaer J, Nielsen S. 2002 Altered expression of renal NHE3, TSC, BSC-1, and ENaC subunits in potassiumdepleted rats. Am J Physiol Renal Physiol. 283:F1376-F1388.
144. Bustamante M, Hasler U, Leroy V, de Seigneux S, Dimitrov M, Mordasini D, Rousselot M, Martin PY, Féraille E. 2008 Calcium-sensing receptor attenuates AVP-induced aquaporin-2 expression via a calmodulin-dependent mechanism. J Am Soc Nephrol. 19:109-116.
145. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC. 1993 Cloning and characterization of an extracellular Ca(2_)-sensing receptor from bovine parathyroid. Nature. 366: 575-580.
146. Riccardi D, Hall AE, Chattopadhyay N, Xu JZ, Brown EM, Hebert SC. 1998 Localization of the extracellular Ca2_/polyvalent cation-sensing protein in rat kidney. Am J Physiol. 274(Pt 2):F611-F622.
147. Procino G, Carmosino M, Tamma G, Gouraud S, Laera A, Riccardi D, Svelto M, Valenti G. 2004 Extracellular calcium antagonizes forskolin-induced aquaporin 2 trafficking in collecting duct cells. Kidney Int. 66:2245-2255.
148. Procino G, Mastrofrancesco L, Tamma G, Lasorsa DR, RanieriM,Stringini G,EmmaF, SveltoM,Valenti G. 2012 Calcium-sensing receptor and aquaporin 2 interplay in hypercalciuria-associated renal concentrating defect in humans. An in vivo and in vitro study. PLoS One. 7:e33145.
149. Puliyanda DP, Ward DT, Baum MA, Hammond TG, Harris Jr HW. 2003 Calpain-mediated AQP2 proteolysis in inner medullary collecting duct. Biochem Biophys Res Commun. 303:52-58.
150. Grace PA. 1994 Ischaemia-reperfusion injury. Br J Surg. 81:637-647.
151. Weight SC, Bell PR, Nicholson ML. 1996 Renal ischaemia-reperfusion injury. Br J Surg. 83:162-170.
152. Novis BK, Roizen MF, Aronson S, Thisted RA. 1994 Association of preoperative risk factors with postoperative acute renal failure. Anesth Analg. 78:143-149.
153. Aronson S, Blumenthal R. 1998 Perioperative renal dysfunction and cardiovascular anesthesia: concerns and controversies. J Cardiothorac Vasc Anesth. 12:567-586.
154. Paller MS. 1994 The cell biology of reperfusion injury in the kidney. J Investig Med. 42:632-639.
155. Hanley MJ. 1980 Isolated nephron segments in a rabbit model of ischemic acute renal failure. Am J Physiol. 239: F17-F23.
156. Tanner GA, Sloan KL, Sophasan S. 1973 Effects of renal artery occlusion on kidney function in the rat. Kidney Int. 4:377-389.
157. Venkatachalam MA, Bernard DB, Donohoe JF, Levinsky NG. 1978 Ischemic damage and repair in the rat proximal tubule: differences among the S1, S2, and S3 segments. Kidney Int. 14:31-49.
158. Kwon TH, Frøkiaer J, Fernández-Llama P, Knepper MA, Nielsen S. 1999 Reduced abundance of aquaporins in rats with bilateral ischemia-induced acute renal failure: prevention by _-MSH. Am J Physiol. 277(Pt 2):F413-F427.
159. Fernández-Llama P, Andrews P, Turner R, Saggi S, Dimari J, Kwon TH, Nielsen S, Safirstein R, Knepper MA. 1999 Decreased abundance of collecting duct aquaporins in post-ischemic renal failure in rats. J Am Soc Nephrol. 10: 1658-1668.
160. Gong H, Wang W, Kwon TH, Jonassen T, Frøkiaer J, Nielsen S. 2003 Reduced renal expression of AQP2, p-AQP2 and AQP3 in haemorrhagic shock-induced acute renal failure. Nephrol Dial Transplant. 18:2551-2559.
161. Tannen RL, Regal EM, Dunn MJ, Schrier RW. 1969 Vasopressin-resistant hyposthenuria in advanced chronic renal disease. N Engl J Med. 280:1135-1141.
162. Teitelbaum I, McGuinness S. 1995 Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA. J Clin Invest. 96:378-385.
163. Kwon TH, Frøkiaer J, Knepper MA, Nielsen S. 1998 Reduced AQP1, -2, and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass. Am J Physiol. 275(Pt 2):F724-F741.
164. Robinson AG. 1976 DDAVP in the treatment of central diabetes insipidus. N Engl J Med. 294:507-511.
165. Geddes BJ, Harding TC, Lightman SL, Uney JB. 1997 Long-term gene therapy in the CNS: reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin. Nat Med. 3:1402-1404.
166. Ideno J, Mizukami H, Honda K, Okada T, Hanazono Y, Kume A, Saito T, Ishibashi S, Ozawa K. 2003 Persistent phenotypic correction of central diabetes insipidus using adeno-associated virus vector expressing arginine-vasopressin in Brattleboro rats. Mol Ther. 8:895-902.
167. Bienemann AS, Martin-Rendon E, Cosgrave AS, Glover CP, Wong LF, Kingsman SM, Mitrophanous KA, Mazarakis ND, Uney JB. 2003 Long-term replacement of a mutated nonfunctional CNS gene: reversal of hypothalamic diabetes insipidus using an EIAV-based lentiviral vector expressing arginine vasopressin. Mol Ther. 7(Pt 1):588-596.
168. Yoshida M, Iwasaki Y, Asai M, Nigawara T, Oiso Y. 2004 Gene therapy for central diabetes insipidus: effective antidiuresis by muscle-targeted gene transfer. Endocrinology. 145:261-268.
169. Kirchlechner V, Koller DY, Seidl R, Waldhauser F. 1999 Treatment of nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride. Arch Dis Child. 80:548-552.
170. Alon U, Chan JC. 1985 Hydrochlorothiazide-amiloride in the treatment of congenital nephrogenic diabetes insipidus. Am J Nephrol. 5:9-13.
171. Knoers N, Monnens LA. 1990 Amiloride-hydrochlorothiazide versus indomethacin-hydrochlorothiazide in the treatment of nephrogenic diabetes insipidus. J Pediatr. 117:499-502.
172. Kim GH, Lee JW, Oh YK, Chang HR, Joo KW, Na KY, Earm JH, KnepperMA,HanJS. 2004 Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin-2, Na-Cl co-transporter, and epithelial sodium channel. J Am Soc Nephrol. 15:2836-2843.
173. Soylu A, Kasap B, Oǧ ün N, OztürkY, Türkmen M, Hoefsloot L, Kavukçu S. 2005 Efficacy of COX-2 inhibitors in a case of congenital nephrogenic diabetes insipidus. Pediatr Nephrol. 20:1814-1817.
174. Pattaragarn A, Alon US. 2003 Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazideand cyclooxygenase-2 inhibitor. Pediatr Nephrol. 18: 1073-1076.
175. Okayasu T, Shigihara K, Kobayashi N, Ishikawa A, Fukushima N, Takase A, Hattori S, Nakajima T, Shishido T, Agatsuma Y. 1990 A family case of nephrogenic diabetes insipidus. Tohoku J Exp Med. 162:137-145.
176. Hochberg Z, Even L,DanonA. 1998 Amelioration of polyuria in nephrogenic diabetes insipidus due to aquaporin-2 deficiency. Clin Endocrinol (Oxf). 49:39-44.
177. Jakobsson B, Berg U. 1994 Effect of hydrochlorothiazide and indomethacin treatment on renal function in nephrogenic diabetes insipidus. Acta Paediatr. 83:522-525.
178. Robben JH, Sze M, Knoers NV, Deen PM. 2007 Functional rescue of vasopressinV2receptor mutants inMDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. Am J Physiol Renal Physiol. 292:F253-F260.
179. Los EL, Deen PM, Robben JH. 2010 Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus. J Neuroendocrinol. 22:393-399.
180. Robben JH, Kortenoeven ML, Sze M, Yae C, Milligan G, Oorschot VM, Klumperman J, Knoers NV, Deen PM. 2009 Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc Natl Acad Sci USA. 106:12195-12200.
181. Morello J.P, Salahpour A, Laperriére A, Bernier V, Arthus M.F, Lonergan M, Petäjä-Repo U, Angers S, Morin D, Bichet D.G, Bouvier M. 2000 Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest. 105:887-895.
182. Wüller S, Wiesner B, Löffler A, Furkert J, Krause G, Hermosilla R, Schaefer M, Schülein R, Rosenthal W, Oksche A. 2004 Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressinV2receptors. J Biol Chem. 279:47254-47263.
183. Serradeil-Le Gal C, Wagnon J, Garcia C, Lacour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, Le Fur G. 1993 Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest. 92:224-231.
184. Bernier V, LagacéM, LonerganM,Arthus MF, Bichet DG, Bouvier M. 2004 Functional rescue of the constitutively internalizedV2vasopressin receptor mutantR137Hby the pharmacological chaperone action of SR49059. Mol Endocrinol. 18:2074-2084.
185. Bernier V, Morello JP, Zarruk A, Debrand N, Salahpour A, Lonergan M, Arthus MF, Laperriére A, Brouard R, Bouvier M, Bichet DG. 2006 Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol. 17:232-243.
186. Jean-Alphonse F, Perkovska S, Frantz MC, Durroux T, Méjean C,MorinD, Loison S, Bonnet D, HibertM,Mouillac B, Mendre C. 2009 Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. J Am Soc Nephrol. 20:2190-2203.
187. Bouley R, Hasler U, Lu HA, Nunes P, Brown D. 2008 Bypassing vasopressin receptor signaling pathways in nephrogenic diabetes insipidus. Semin Nephrol. 28:266-278.
188. Bouley R, Breton S, Sun T, McLaughlin M, Nsumu NN, Lin HY, Ausiello DA, Brown D. 2000 Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells. J Clin Invest. 106:1115-1126.
189. Wang W, Li C, Nejsum LN, Li H, Kim SW, Kwon TH, Jonassen TE, Knepper MA, Thomsen K, Frøkiaer J, Nielsen S. 2006 Biphasic effects of ANP infusion in conscious, euvolumic rats: roles of AQP2 and ENaC trafficking. Am J Physiol Renal Physiol. 290:F530-F541.
190. Bouley R, Pastor-Soler N, Cohen O, McLaughlin M, Breton S, Brown D. 2005 Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra). Am J Physiol Renal Physiol. 288:F1103-F1112.
191. Sanches TR, Volpini RA, Massola Shimizu MH, Bragança AC, Oshiro-Monreal F, Seguro AC, Andrade L. 2012 Sildenafil reduces polyuria in rats with lithium-induced NDI. Am J Physiol Renal Physiol. 302:F216-F225.
192. Bichet DG, Ruel N, Arthus MF, Lonergan M. 1990 Rolipram, a phosphodiesterase inhibitor, in the treatment of two male patients with congenital nephrogenic diabetes insipidus. Nephron. 56:449-450.
193. Bouley R, Lu HA, Nunes P, Da Silva N, McLaughlin M, Chen Y, Brown D. 2011 Calcitonin has a vasopressin-like effect on aquaporin-2 trafficking and urinary concentration. J Am Soc Nephrol. 22:59-72.
194. de Rouffignac C, Elalouf JM. 1983 Effects of calcitonin on the renal concentrating mechanism. Am J Physiol. 245: F506-F511.
195. Li W, Zhang Y, Bouley R, Chen Y, Matsuzaki T, Nunes P, Hasler U, Brown D, Lu HA. 2011 Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase. Am J Physiol Renal Physiol. 301: F309-F318.
196. Procino G, Barbieri C, Carmosino M, Tamma G, Milano S, De Benedictis L, Mola M G., Lazo-Fernandez Y, Valenti G, Svelto M. 2011 Fluvastatin modulates renal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells. Pflugers Arch. 462:753-766.
197. Olesen ET, Rützler MR, Moeller HB, Praetorius HA, Fenton RA. 2011 Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus. Proc Natl Acad Sci USA. 108:12949-12954.
198. Steinwall M, Akerlund M, Bossmar T, Nishii M, Wright M. 2004 ONO-8815Ly, an EP2 agonist that markedly inhibits uterine contractions in women. BJOG. 111:120-124.
199. Shi PP, Cao XR, Qu J, Volk KA, Kirby P, Williamson RA, Stokes JB, Yang B. 2007 Nephrogenic diabetes insipidus in mice caused by deleting COOH-terminal tail of aquaporin-Am J Physiol Renal Physiol. 292:F1334-F1344.
200. McDill BW, Li SZ, Kovach PA, Ding L, Chen F. 2006 Congenital progressive hydronephrosis (cph) is caused by an S256L mutation in aquaporin-2 that affects its phosphorylation and apical membrane accumulation. Proc Natl Acad Sci U S A. 103:6952-6957